Messing honored for advancing urological care
Edward Messing, M.D., F.A.C.S., has been recognized by the American Urological Association (AUA) for 35 years of accomplishment in improving care for individuals with bladder, kidney, prostate, and testicular cancer. Messing will receive the Ramon Guiteras Award at the AUA’s annual meeting in May in San Francisco.
The award is presented annually to an individual deemed to have made outstanding contributions to the art and science of urology. Founded in 1902, AUA is the leading national and international educational, scientific, and clinical organization for the specialty of urology with more than 20,000 members worldwide. Guiteras was one of the founders of the AUA and the award named in his honor is considered the organization’s most prestigious recognition.
Messing, a professor in the University of Rochester Medical Center Department of Urology and the Wilmot Cancer Institute, is a renowned expert in the diagnosis and treatment of genitourinary cancers. His research contributions have ranged from enhancing our knowledge of the basic molecular and genetic components that contribute to the development and progression of cancers of the bladder, prostate, and kidney, and translating this research into new ways to detect, prevent, and treat these diseases.
He has also designed and conducted landmark phase III clinical trials for each of these cancers, led a bladder cancer study that resulted in a simple in-office urine test to screen for the disease, and has helped shape the national recommendations for the screening of prostate cancer and the use of radiation to treat forms of the disease.
Dr. Messing received his medical degree from New York University (NYU) in 1972 and conducted his training at NYU, Stanford University, and the University of California, Los Angeles. He served on the faculty at the University of Wisconsin for 13 years before arriving at the University of Rochester Medical Center in 1995 to become chair of the Department of Urology, a position he held until January 1, 2018.